Aim Immunotech Inc (AIM) Return on Investment ROI from the first quarter of 2026 to first quarter of 2025 and for the year 2026, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
Aim Immunotech Inc's ROI from its first quarter of 2026 to the first quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Aim Immunotech Inc's ROI in the first quarter of 2026?
Due to the stockholders deficit and subsequent negative measured investments, it was not possible to calculate Aim Immunotech Inc 's return on investment (ROI) in its first quarter of 2026
AIM ImmunoTech Inc.: Navigating Financial Turbulence Amidst Strategic Ambitions in the Post-COVID Healthcare LandscapeIn a recent press release dated February 11, 2025, AIM ImmunoTech Inc. (NYSE American: AIM) made a crucial announcement concerning its financial offerings. The biotechnology firm revealed that it would be postponing any offering under its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ending December 31, 2024. This decision comes at a pivotal moment as the company grapples with significant financial challenges and seeks to recalibrate its strategic roadmap.AIM ImmunoTech, perhaps best known for its ongoing work on the promising immunotherapy drug Ampligen (rintatolimod), has aspirations that fuel its optimistic outlook for the coming years. The company has earmarked critical areas of focus, including pancreatic cancer and the lingering effects of Long COVID, highlighting its commitment to addressing unmet medical needs in the healthcare sector. In its optimistic messaging, AIM emphasizes its milestones for 2024 and posits that it is steadily charting a course toward success in the tumultuous post-COVID healthcare environment.
AIM ImmunoTech s Tumultuous Road: High Hopes vs. Historic Losses in the Post-COVID Healthcare LandscapeAIM ImmunoTech Inc. a biotechnology company known for its work on the immunotherapy drug Ampligen (rintatolimod), has made an ambitious bid for redemption as it navigates the complexities of the post-COVID healthcare era. The company recently released a bullish commentary on its milestones for 2024 and painted an optimistic picture for 2025-26, highlighting its focus on areas with critical unmet medical needs, particularly pancreatic cancer and Long COVID.Yet beneath the surface of its strategic narrative lies a troubling financial reality. For the 12 months ending in the third quarter of 2024, AIM ImmunoTech reported a staggering cumulative net loss of $24 million, translating to a disheartening return on investment (ROI) of -376.15%. Against this bleak backdrop, the company is juxtaposed with 831 other firms in the healthcare sector that reported higher ROI figures, raising eyebrows about its competitive positioning.
AIM ImmunoTech s Strategic Funding Move Raises Questions Amidst Challenging Financial Performance In a recent announcement, AIM ImmunoTech Inc. revealed the pricing details of its registered direct offering to raise $2.0 million. The company entered into a securities purchase agreement with a single institutional investor, who agreed to purchase 5,640,958 shares of common stock at a price of $0.363 per share. This offering also includes unregistered Class A and Class B warrants, allowing the investor to purchase additional shares in the future. These financial maneuvers come at a critical time for AIM ImmunoTech, as recent financial reports indicate a significant cumulative net loss of $-31 million during the 12 months leading up to the first quarter of 2024. This unfortunate result has resulted in a negative return on investment (ROI) of -181.06%.
In a recent announcement, AIM ImmunoTech Inc. (NYSE American: AIM) disclosed the release of the latest CEO Corner segment, shedding light on the company s clinical development program and its focus on addressing the unmet needs of patients with Advanced Recurrent Ovarian Cancer. Thomas Equels, the Chief Executive Officer of AIM ImmunoTech, shared insights into the disease s burden and emphasized the urgency to develop effective treatment options. Advanced Recurrent Ovarian Cancer is a challenging condition associated with high rates of recurrence and limited treatment success. Equels highlighted the critical unmet need for innovative therapies that can improve patient outcomes. As part of its clinical development program, AIM ImmunoTech is actively pursuing strategic milestones aimed at tackling this pressing medical challenge. The company recognizes the significance of progressing potential treatments to meet the demands of patients and healthcare providers alike. Despite the promising potential, AIM ImmunoTech also faces certain financial hurdles. During the third quarter of 2023, the company reported a cumulative net loss of $21 million, resulting in a negative return on investment (ROI) of -65.85%. This financial indicator highlights the risks associated with developing innovative therapies in the highly regulated healthcare industry.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
